- Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
- Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
- Fulcrum Therapeutics to Participate in Upcoming May Conferences
- Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
- Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
- Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
More ▼
Key statistics
On Thursday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 8.37, -38.91% below its 52-week high of 13.70, set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.69 |
---|---|
High | 8.69 |
Low | 8.21 |
Bid | 8.20 |
Offer | 8.74 |
Previous close | 8.65 |
Average volume | 513.84k |
---|---|
Shares outstanding | 62.15m |
Free float | 61.29m |
P/E (TTM) | -- |
Market cap | 487.91m USD |
EPS (TTM) | -1.61 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼